PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation

Disease relapse remains the leading cause of failure after autologous stem cell transplantation (ASCT) for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). We conducted a phase 2, multicenter, single-arm study of the anti–PD-1 monoclonal antibody pembrolizumab given after...

詳細記述

保存先:
書誌詳細
出版年:Blood Adv
主要な著者: Frigault, Matthew J., Armand, Philippe, Redd, Robert A., Jeter, Erin, Merryman, Reid W., Coleman, Kimberly C., Herrera, Alex F., Dahi, Parastoo, Nieto, Yago, LaCasce, Ann S., Fisher, David C., Ng, Samuel Y., Odejide, Oreife O., Freedman, Arnold S., Kim, Austin I., Crombie, Jennifer L., Jacobson, Caron A., Jacobsen, Eric D., Wong, Jeffrey L., Bsat, Jad, Patel, Sanjay S., Ritz, Jerome, Rodig, Scott J., Shipp, Margaret A., Chen, Yi-Bin, Joyce, Robin M.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2020
主題:
Lymphoid Neoplasia
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6960482/
https://ncbi.nlm.nih.gov/pubmed/31917843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000784
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料